Plasma YKL-40 as a biomarker for bevacizumab efficacy in patients with newly diagnosed glioblastoma in the phase 3 randomized AVAglio trial

por Boisen, Mogens K., Holst, Camilla B., Consalvo, Nicola, Chinot, Olivier L., Johansen, Julia S.
Publicado 2017

Evaluation of Angiopoietin-2 as a biomarker in gastric cancer: results from the randomised phase III AVAGAST trial

por Hacker, Ulrich T, Escalona-Espinosa, Laura, Consalvo, Nicola, Goede, Valentin, Schiffmann, Lars, Scherer, Stefan J, Hedge, Priti, Van Cutsem, Eric, Coutelle, Oliver, Büning, Hildegard
Publicado 2016